Technical analysis of Krystal Biotech, Inc. (KRYS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa.
Price Performance
| 1 month | -8.19% |
| 3 months | -9.17% |
| Year-to-date | +20.02% |
| 1 year | +49.56% |
| 3 years | +142.24% |
| 5 years | +475.12% |
52-Week Range
| 52-week High | $382.54 |
| 52-week Low | $184.02 |
| Avg Volume (90d) | 366K |
Technical Indicators
| SMA 50 | $336.45 |
| SMA 200 | $308.60 |
| Beta | 0.54 |
| 30-day Volatility (annualised) | 46.8% |
| Price vs SMA 50 | -12.1% |
| Price vs SMA 200 | -4.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $246.54 | |
| 2026-01 | $279.24 | +13.3% |
| 2026-02 | $275.64 | -1.3% |
| 2026-03 | $258.32 | -6.3% |
| 2026-04 | $262.26 | +1.5% |
| 2026-05 | $309.03 | +17.8% |
| 2026-06 | $371.67 | +20.3% |
| 2026-07 | $341.12 | -8.2% |
| 2026-08 | $359.36 | +5.3% |
| 2026-09 | $332.56 | -7.5% |
| 2026-10 | $332.29 | -0.1% |
| 2026-11 | $295.90 | -11.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-02 | $1.79 | $126M |
| 2026-08-03 | $1.70 | $121M |
| 2026-05-04 | $1.45 | $112M |
| 2026-02-17 | $1.62 | $105M |
| 2025-11-03 | $1.12 | $105M |
| 2025-08-04 | $1.08 | $95M |
Price
| Price | $295.90 (closing price, November 2, 2026) |
| Market Cap | $8.8B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 40.15 |
| Price / Book | 6.10 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.89 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 39.03 |